drugset / Trial / NCT00556257
Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients
RandomizedParallel-groupOpen-labelPrevention
Summary
A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.
Timeline
- Start
- 2007-08
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | — | — |
| Subject | Tofacitinib | Small molecule | 15 mg | — |
Indications
No indication recorded.